Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Itolizumab · EQ-001, BMAB-600

Monoclonal antibody · Antagonist of CD6 · developed by Biocon

Phase 3 Most advanced trial (none active)
2 Registered trials

What is Itolizumab?

Itolizumab is a humanized IgG1 monoclonal antibody that binds CD6, a co-stimulatory molecule on T cells involved in their adhesion and maturation. By blocking CD6-mediated activation pathways, it downregulates T-cell activation and reduces pro-inflammatory cytokine synthesis. It is studied in asthma and graft-versus-host disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EQ-001, BMAB-600
Drug type
Monoclonal antibody
Targets
CD6
Mechanism
Antagonist of CD6
Pathways
T-cell activation and differentiation, pro-inflammatory cytokine synthesis
Therapy area
Immunology, Respiratory
Developer
Biocon Limited
In trials of
EQ
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
XQQ2RHV14N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05263999 Phase 3 Graft Versus Host Disease Terminated EQ
NCT04007198 Phase 1 Asthma Completed EQ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute GVHDAcute-graft-versus-host DiseaseaGVHDAsthmaGraft Versus Host DiseaseGVHD

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.